TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neurosense Therapeutics Ltd. ( (NRSN) ) just unveiled an update.
On December 4, 2025, NeuroSense Therapeutics announced plans for a pre-NDS meeting with Health Canada in April 2026 to discuss the regulatory advancement of PrimeC for ALS. The company is optimistic about the regulatory pathway in Canada and anticipates a potential NDS submission by mid-2026, which could impact its operations and market positioning positively.
The most recent analyst rating on (NRSN) stock is a Buy with a $7.50 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.
Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for debilitating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease. The company aims to address significant unmet medical needs by developing combined therapies targeting multiple pathways associated with these diseases.
Average Trading Volume: 617,694
Technical Sentiment Signal: Sell
Current Market Cap: $33.69M
Find detailed analytics on NRSN stock on TipRanks’ Stock Analysis page.